Drugs / Licensed TIV-HD1
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03282240 Comparator | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Licensed TIV-HD1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282240 ↗ |
| Modality | Vaccine | “A high-dose, split-virion inactivated trivalent influenza vaccine (IIV3-HD; Fluzone® High-Dose, Sanofi Pasteur) is available for adults ≥65 years of age.” PMID 31431411 ↗ Aug 2019 |
| Route | Intramuscular | “administered IM into the upper arm area” NCT03282240 ↗ |